A two-drug treatment regimen works better than monotherapy for incontinent overactive bladder patients, researchers reported at the AUA annual meeting in New Orleans.
The beta-3 adrenergic agonist mirabegron (Myrbetriq) used as add-on therapy with the antimuscarinic drug solifenacin (VESIcare) proved more effective in treating overactive bladder than solifenacin alone in the phase IIIb BESIDE clinical trial. The international trial studied 2,174 patients with similar demographic and baseline characteristics who had had an inadequate response to 4 weeks of monotherapy with solifenacin, 5 mg daily.
Patients were randomized to receive 12 weeks of combination therapy (solifenacin, 5 mg daily plus mirabegron, 50 mg [25 mg daily of mirabegron during the first 4 weeks]), monotherapy with 5 mg of solifenacin daily, or monotherapy with 10 mg of solifenacin daily. Researchers evaluated the change in mean number of incontinence episodes per 24 hours between baseline and end of treatment (the primary efficacy endpoint) and change in mean number of micturitions per 24 hours. They also assessed the number of incontinence episodes during a 3-day diary at the end of treatment.
More on OAB